New medical technologies are a leading driver of U.S. health care spending. This report identifies promising policy options to change which medical technologies are created, with two related policy goals: (1) Reduce total health care spending with the smallest possible loss of health benefits,...

The questions tackled in this paper are: How do we deal with ethically contested medical innovations?, and Can we do better? First, I analyse how we deal with these problems by a division of labour and competitive boundary work between the medical R&D system's research and technological...

Der Schutz der Gesundheit verlangt medizinischen Fortschritt und die tatsächliche Verfügbarkeit von Spitzenmedizin. Allerdings werden damit zusammenhängende Ausgabensteigerungen angesichts der „Kostendämpfungsmaxime"" oft als Fehlentwicklung wahrgenommen. Der Aufsatzband stellt diese...

We develop a model of innovation that enables us to trace the interplay among three key dimensions of the innovation process: (i) demand of and (ii) supply for innovation, and (iii) technological capabilities available to generate innovation in the forms of products, processes, and services....

This study explores the role of intellectual property (IP) in developing and commercializing melanoma biomarkers within the pharmaceutical market, focusing on precision medicine (PM). It investigates five key areas: (i) inventiveness dynamics, (ii) commercial and epidemiological motivations for...